# Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease

> **NCT01427244** · PHASE2 · WITHDRAWN · sponsor: **Yale University**

## Conditions studied

- Paget's Disease of the Vulva

## Interventions

- **DRUG:** trastuzumab

## Key facts

- **NCT ID:** NCT01427244
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-08
- **Primary completion:** 2014-09
- **Final completion:** 2015-09
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2014-06-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01427244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01427244, "Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01427244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*